Idaho joined 37 other states in a $181 million settlement with Johnson and Johnson subsidiary Janssen Pharmaceuticals Inc., resolving allegations that Janssen unfairly and deceptively marketed some antipsychotic drugs.
Federal law says drug companies can't promote their drugs for uses that haven't yet been approved by the Food and Drug Administration, though doctors can prescribe drugs for those uses. The states said Janssen marketed three Risperdal-brand drugs for unapproved uses, targeting patients with Alzheimer's disease, dementia, depression and anxiety.
Janssen will pay Idaho $2.85 million as its share of the settlement. The company also said it will not promote and market the drugs for unapproved uses and won't lie, mislead or otherwise be deceptive in its drug promotions.
The settlement spelled out how the company will disclose risks in black-box warnings on its product labels, how it will respond to health care providers who ask for information, and how it won't give bonuses to marketing and sales people to encourage or reward unapproved uses.
Idaho's settlement money will be deposited into the account that helps pay for Attorney General Lawrence Wasden's consumer protection operations.
In agreeing to the settlement, Janssen Pharmaceuticals admitted no wrongdoing.